@drrgjoneslab.bsky.social
Hoping that these new insights will lead to new clinical trials and inflammation-targeting therapies for PJS patients!
June 27, 2025 at 11:46 AM
Hoping that these new insights will lead to new clinical trials and inflammation-targeting therapies for PJS patients!
In the current paper we report that LKB1 mutations promote "pathogenic" Th17 responses in the GI tract. Polyps from PJS mice are also enriched with IL-17-producing CD4+, CD8+, and gamma-delta T cells. Treatment of PJS mice with IL-17 blocking antibodies reduces GI polyp growth!
June 27, 2025 at 11:45 AM
In the current paper we report that LKB1 mutations promote "pathogenic" Th17 responses in the GI tract. Polyps from PJS mice are also enriched with IL-17-producing CD4+, CD8+, and gamma-delta T cells. Treatment of PJS mice with IL-17 blocking antibodies reduces GI polyp growth!
This work builds on our previous unexpected finding that gastrointestinal (GI) polyps found in PJS could be triggered by T cells of the immune system. This work indicated that inflammation by the immune system was a driver of tumor growth in PJS.
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
LKB1 deficiency in T cells promotes the development of gastrointestinal polyposis
T cell–mediated inflammation promotes Peutz–Jeghers syndrome.
www.science.org
June 27, 2025 at 11:43 AM
This work builds on our previous unexpected finding that gastrointestinal (GI) polyps found in PJS could be triggered by T cells of the immune system. This work indicated that inflammation by the immune system was a driver of tumor growth in PJS.
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...